Tecan reports return to sales growth and strong order entry in the second half of 2025

Core Insights - Tecan reported a return to sales growth and strong order entry in the second half of 2025, with full-year sales in local currencies aligning with previous forecasts [1][2] Sales Performance - Group sales for 2025 decreased by 1.6% in local currencies and 5.5% in Swiss francs, totaling CHF 882.5 million compared to CHF 934.3 million in 2024 [2] - In the second half of 2025, Tecan experienced moderate sales growth, with a 0.4% increase in local currencies, while sales in Swiss francs declined by 5.2% to CHF 443.0 million [2] Order Entry - Full-year order entry reached CHF 900.9 million, a decline of 0.3% in Swiss francs but an increase of 3.8% in local currencies compared to 2024 [3] - In the second half of 2025, order entry grew by 8.6% in local currencies and by 2.6% in Swiss francs [3] Segment Sales - Life Sciences Business sales were CHF 377.1 million, down 1.0% in local currencies and 5.0% in Swiss francs [5] - Partnering Business recorded sales of CHF 505.4 million, representing a decrease of 2.0% in local currencies and 5.9% in Swiss francs [5] Profitability and Outlook - Tecan reaffirmed its adjusted EBITDA margin guidance for 2025, as previously announced [6] - The company anticipates a return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies under normal market conditions, with gradual recovery expected in end markets [7]